Plasma levels of trastuzumab in gastric cancer: Case report
Introduction The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the clinical effectiveness of this treatment, affecting progression-free survival and overall survival. Case report We report the case of a patient with metastatic HER2-positivegastric cancer, receiving XELOX (fluoropyrimidine and oxaliplatin) plus trastuzumab at standard doses, who presented sub-therapeutic serum levels during the first two treatment cycles and rapid disease progression (progression-free survival = 5.6 months). Discussion This case reveals a possible cause of poor effectiveness of trastuzumab treatment for metastatic gastric cancer in some patients, namely low circulating levels of the drug. It highlights the importance of monitoring as a possible tool for individual dose adjustment to optimize this therapy..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of oncology pharmacy practice - 23(2017), 8, Seite 635-637 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
González-García, J [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1177/1078155216670228 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC199963604X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC199963604X | ||
| 003 | DE-627 | ||
| 005 | 20230715084831.0 | ||
| 007 | tu | ||
| 008 | 171228s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1078155216670228 |2 doi | |
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC199963604X | ||
| 035 | |a (DE-599)GBVOLC199963604X | ||
| 035 | |a (PRQ)c1150-9ea13d13bbf6e39b82152f725b5e206af6a10b4ec34339c111e277babd6699050 | ||
| 035 | |a (KEY)0296819320170000023000800635plasmalevelsoftrastuzumabingastriccancercasereport | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 100 | 1 | |a González-García, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma levels of trastuzumab in gastric cancer: Case report |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Introduction The use of trastuzumab with a fluoropyrimidine and platinum compound is currently the standard first-line treatment of patients with metastatic HER2-positive gastric cancer, but it appears that serum levels of trastuzumab determine the clinical effectiveness of this treatment, affecting progression-free survival and overall survival. Case report We report the case of a patient with metastatic HER2-positivegastric cancer, receiving XELOX (fluoropyrimidine and oxaliplatin) plus trastuzumab at standard doses, who presented sub-therapeutic serum levels during the first two treatment cycles and rapid disease progression (progression-free survival = 5.6 months). Discussion This case reveals a possible cause of poor effectiveness of trastuzumab treatment for metastatic gastric cancer in some patients, namely low circulating levels of the drug. It highlights the importance of monitoring as a possible tool for individual dose adjustment to optimize this therapy. | ||
| 540 | |a Nutzungsrecht: © The Author(s) 2016 | ||
| 700 | 1 | |a Alonso-Alvarez, B |4 oth | |
| 700 | 1 | |a Nazco-Casariego, GJ |4 oth | |
| 700 | 1 | |a Batista-López, N |4 oth | |
| 700 | 1 | |a Guttiérrez-Nicolás, F |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of oncology pharmacy practice |d London : Sage, 1995 |g 23(2017), 8, Seite 635-637 |w (DE-627)214115674 |w (DE-600)1330764-2 |w (DE-576)435516299 |x 1078-1552 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:8 |g pages:635-637 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1177/1078155216670228 |3 Volltext |
| 856 | 4 | 2 | |u http://journals.sagepub.com/doi/full/10.1177/1078155216670228 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2017 |e 8 |h 635-637 | ||